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Background: Secondary hyperparathyroidism (SHPT) is one of the common complications 
in dialysis patients, and is associated with increased risk of vascular calcification. The effects 
of cinacalcet hydrochloride treatment on bone and mineral metabolism have been previously 
reported, but the benefit of cinacalcet on vascular calcification remains uncertain. The aim of 
this study was to evaluate the impact of cinacalcet on abdominal aortic calcification in dialysis 
patients.
Subjects and methods: Patients were on maintenance hemodialysis with insufficiently con-
trolled SHPT (intact parathyroid hormone [PTH] .180 pg/mL) by conventional therapies. All 
subjects were initially administered 25 mg cinacalcet daily, with concomitant use of calcitriol 
analogs. Abdominal aortic calcification was annually evaluated by calculating aortic calcifica-
tion area index (ACAI) using multidetector computed tomography (MDCT), from 12 months 
before to 36 months after the initiation of cinacalcet therapy.
Results: Twenty-three patients were analyzed in this study. The mean age was 59.0±8.7 years, 
34.8% were women, and the mean dialysis duration was 163.0±76.0 months. After administration 
of cinacalcet, serum levels of intact PTH, phosphorus, and calcium significantly decreased, and 
mean Ca × P values significantly decreased from 67.4±7.9 mg2/dL2 to 52±7.7 mg2/dL2. Although 
the ACAI value did not decrease during the observation period, the increase in ACAI between 
24 months and 36 months after cinacalcet administration was significantly suppressed.
Conclusion: Long-term administration of cinacalcet was associated with reduced progression 
of abdominal aortic calcification, and achieving appropriate calcium and phosphorus levels may 
reduce the rates of cardiovascular events and mortality in patients on hemodialysis.
Keywords: abdominal aortic calcification, cinacalcet hydrochloride, hemodialysis
Introduction
Patients with chronic kidney disease (CKD) undergoing dialysis have a higher 
risk of cardiovascular disease and mortality.1 Vascular calcification is frequently 
observed among patients with CKD, and associations between vascular calcification 
and increased risk of mortality have been reported in several studies.2–5 Secondary 
hyperparathyroidism (SHPT) is a common complication observed in dialysis patients.6 
Goodman et al reported that elevation of calcium–phosphorus product is associated 
with cardiovascular events and vascular calcification,7 and mineral and bone disorders 
induced by SHPT have been considered to increase the risk of vascular calcification. 
Also, a high serum parathyroid hormone (PTH) concentration is associated with car-
diovascular events and mortality.8–11
Cinacalcet hydrochloride (cinacalcet) is a calcimimetic agent that allosterically 
modulates the calcium-sensing receptor. It reduces serum PTH concentrations, and 
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also decreases serum calcium and phosphorus concentrations 
simultaneously. To date, there have been several reports 
regarding treatment with cinacalcet easily achieving the 
target range of calcium, phosphorus, and PTH concentrations 
compared to conventional therapy for SHPT.12–15 In animal 
studies, pleiotropic effects of cinacalcet, such as improve-
ment of parathyroid hyperplasia, osteitis fibrosa, osteoporosis, 
and vascular calcification have been shown.16–22 In dialysis 
patients, Tsuruta et al demonstrated improved coronary artery 
calcification scores by administration of cinacalcet.23 More 
recently, Raggi et al suggested that cinacalcet may attenuate 
calcification of coronary artery in patients on hemodialysis 
in the ADVANCE (Study to Evaluate Cinacalcet Plus Low-
Dose Vitamin D on Vascular Calcification in Subjects with 
Chronic Kidney Disease Receiving Hemodialysis) trial,24 but 
investigations in regard to the effect of cinacalcet on vascular 
calcification are still quite few, and the clinical benefit of 
cinacalcet remains uncertain.
The aim of this study was to evaluate the associations 
between treatment with cinacalcet and the progression of 
vascular calcification among patients on maintenance hemo-
dialysis with inadequately controlled SHPT by conventional 
therapies.
Subjects and methods
Patient selection
Subjects were 18 years or older, had undergone hemodialysis 
for .12 months at Shigei Medical Research Hospital, 
Okayama, Japan, and had biochemical evidence of SHPT with 
intact PTH concentrations .180 pg/mL during treatment with 
calcitriol analogs. Albumin-corrected serum calcium concen-
trations were .8.4 mg/dL, and aortic calcification area index 
(ACAI)25 at screening was 0 or .60 in all subjects, as measured 
by multidetector computed tomography (MDCT). The trial 
was conducted according to the principles of the Declaration 
of Helsinki. The study protocol was approved by the ethics 
committee of Shigei Medical Research Hospital, and written 
informed consent was obtained from all participants.
study protocol
The current investigation was a prospective cohort study in 
a single hospital, with all subjects treated with cinacalcet 
hydrochloride at a starting dose of 25 mg/day. The dose 
was allowed to be adjusted in an attempt to achieve the 
target ranges specified in the Japanese Society for Dialysis 
Therapy (JSDT) guideline (calcium 8.4–10.0 mg/dL, phos-
phorus 3.5–6.0 mg/dL, intact PTH 60–180 pg/mL).26 Changes 
in cinacalcet dosage were recorded throughout the follow-up 
period, and the maximum dose of cinacalcet adminis-
tered was 100 mg. For conventional therapy, the subjects 
received various doses of calcitriol analogs either orally or 
 intravenously. Concomitant treatment with phosphate binders 
was also permitted and could be adjusted without restriction 
throughout the study. The duration of each dialysis treatment 
was 4–4.5 hours, and blood samples were drawn once a month 
at the beginning of the first hemodialysis session of the week. 
Systolic and diastolic blood pressures were measured in the 
supine position after 10–15 minutes’ rest.
Imaging evaluation
We measured the ACAI25 using MDCT from 12 months 
before cinacalcet was started, and every 12 months thereafter, 
until 36 months after cinacalcet administration. Thus, we 
evaluated the percent annual change in the ACAI during the 
follow-up period. In Figure 1, the change in ACAI score in 
a representative case is shown. Using MDCT, the area above 
Baseline 12 months 24 months 36 months
12.8% 15.4% 26.8% 30.4%
Figure 1 Aortic calcification area index (ACAI) in a representative case from baseline to 36 months after cinacalcet administration. ACAI is measured as follows. The area 
above the bifurcation of the common iliac artery is scanned ten times at 1 cm intervals. These scans are then analyzed by ImageJ (National Institutes of Health, Bethesda, MD, 
USA) to calculate the area of calcification in the abdominal aorta and the cross-sectional area of the aorta to calculate the calcified area as a percentage. The ACAI is expressed 
as the average calcification index of ten scans.
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bifurcation of the common iliac artery is scanned ten times 
at 1 cm intervals. These scans are then analyzed by ImageJ27 
(National Institutes of Health, Bethesda, MD, USA) to cal-
culate the area of calcification in the abdominal aorta and 
the cross-sectional area of the aorta to calculate the calcified 
area as a percentage. The ACAI is expressed as the average 
calcification index of ten scans.
statistical analysis
Results are reported as means ± standard deviation, unless 
otherwise indicated. Annual change in ACAI score, serum 
albumin-corrected calcium, serum phosphorus, calcium–
phosphorus product, and intact PTH values were analyzed by 
repeated measures analysis of variance followed by Tukey’s 
post hoc test. Also, the change in ACAI/year was analyzed by 
unpaired t-test between the group of treatment with lanthanum 
carbonate and the others. Stepwise multivariate regression 
analysis was performed using %ACAI (month 24/month 36/
month -12/0) = (ACAI [month 36]/ACAI [month 24])/(ACAI 
[month 0]/ACAI [month -12]) as a dependent variable. 
 Independent variables were sex and absolute changes in phos-
phorus, calcium–phosphorus product, and intact PTH from 
baseline to 36 months after cinacalcet administration. Doses of 
calcitriol analogs considered to be equivalent were 10 µg maxa-
calcitol =1.5 µg calcitriol, and all results for injectable active 
calcitriol analog dosages are presented as calcitriol equivalents. 
Statistical analyses were performed by SPSS software (version 
20.0; IBM, Armonk, NY, USA). For all comparisons, P,0.05 
was considered statistically significant.
Results
study population and baseline results
Of 47 participants in the study, 43 completed 36 months of 
 treatment. The reasons for early withdrawal included death 
(n=3) and kidney transplantation (n=1). None of the deaths 
were considered related to cinacalcet. Of the 43 patients who 
completed the study, no MDCT scan (n=12), ACAI .60 (n=2), 
ACAI =0 (n=2), and twisted abdominal aorta (n=4) were 
excluded, because their aortas were not appropriate to assess the 
progression of  calcification. Finally, a total of 23 subjects were 
available for efficacy analysis. Table 1 shows the baseline charac-
teristics at month 0. The mean age of 23 subjects who completed 
the study was 59.0±8.7 years, 34.8% were women, and mean 
dialysis duration was 163.0±76.0 months. All patients had intact 
PTH levels .180 pg/mL.  Approximately 70% of the subjects 
were receiving injectable active calcitriol analogs at enrollment, 
and the mean dose was 1.56±1.26 µg/week of calcitriol equiva-
lents. Almost all were receiving phosphate binders.
effect of cinacalcet on intact PTh  
and mineral metabolism
Figure 2 shows the change in serum levels of intact PTH, 
calcium, and phosphorus from baseline to the end of the 
follow-up period. Subjects started receiving 25 mg/day of 
cinacalcet at baseline, and the mean dosage of cinacalcet 
was 46.2±29.8 mg/day at 36 months. None of the subjects 
had to discontinue treatment with cinacalcet due to side 
effects or noncompliance. After administration of cinacalcet, 
serum intact PTH levels decreased from 473.4±220.1 pg/mL 
at baseline to 163.0±94.8 pg/mL at 12 months (Figure 2A, 
P,0.001), and then remained stable throughout the study 
period. After 36 months of cinacalcet treatment, 78.3% of 
subjects achieved intact PTH concentration below the upper 
limit of the JSDT target range. The mean serum phosphorus 
concentration decreased from 6.7±0.8 mg/dL to 5.6±0.9 mg/dL 
(Figure 2B, P,0.001), and the mean corrected serum calcium 
concentration also decreased, from 10.1±0.6 to 9.4±0.6 mg/dL 
(Figure 2C, P=0.001). The mean Ca × P values were signifi-
cantly decreased from 67.4±7.9 mg2/dL2 to 52.0±7.7 mg2/dL2 
(Figure 2D, P,0.001). After 36 months of treatment, subjects 
who achieved Ca × P ,55 mg2/dL2 increased from 4.4% to 
65.2%.
Use of calcitriol analogs  
and phosphate binders
The use and dose of intravenous active calcitriol analogs 
remained largely unchanged from baseline to 36 months. 
Similarly, the percentages of the subjects taking sevelamer 
Table 1 Baseline demographic and medication characteristics 
(n=23)
Age (years) 59±8.7
Sex (female, %) 34.8
Hemodialysis duration (months) 163±76
Diabetes mellitus (%) 13
BMI (kg/m2) 21.12±3.31
Systolic blood pressure (mmHg) 135±17.9
Diastolic blood pressure (mmHg) 73.2±11.3
History of calcium carbonate use (%) 78.3
History of sevelamer hydrochloride use (%) 13
History of lanthanum carbonate use (%) 0
Baseline vitamin D use (%) 69.6
Serum intact PTH (pg/mL) 473.4±220.1
Corrected serum calcium (mg/dL) 10.11±0.59
Serum phosphorus (mg/dL) 6.59±0.81
Serum albumin (g/dL) 3.64±0.29
Serum ALP (U/L) 262.1±89.2
Note: Values are means ± standard deviation.
Abbreviations: BMI, body mass index; PTH, parathyroid hormone; ALP, alkaline 
phosphatase.
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hydrochloride and calcium carbonate were stable throughout 
the study period (Table 2). After 24 months of cinacalcet 
administration, 65.2% of the subjects were treated with 
lanthanum carbonate.
Effect of cinacalcet on aortic calcification
The change in ACAI score for an individual subject and 
mean values over the observation period are presented in 
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Figure 2 (A–D) Serum levels of intact parathyroid hormone (PTH), calcium, and phosphorus from baseline to the end of the follow-up period. After administration of 
cinacalcet, serum intact PTh levels decreased from 473.4±220.1 pg/mL at baseline to 163.0±97.0 pg/mL at 12 months (P,0.001) (A) and then remained stable through the 
study period. The mean serum phosphorus concentration decreased from 6.7±0.8 mg/dL at baseline to 5.6±0.9 mg/dL at 36 months (P,0.001) (B), and the mean corrected 
serum calcium concentration also decreased, from 10.1±0.6 to 9.4±0.6 mg/dL (P=0.001) (C). The mean Ca × P values significantly decreased from 67.4±7.9 mg2/dL2 to 
52±7.7 mg2/dL2 for 36 months (P,0.001) (D) *P,0.05; **P,0.01. 
Abbreviations: ca, calcium; P, inorganic phosphate.
Figure 3A and B, respectively. The mean ACAI value was 
21.4% at baseline, 23.9% at 12 months, 23.7% at 24 months, 
and 24.3% at 36 months (Figure 3B). The annual percentage 
changes in ACAI score from 12 months before cinacalcet 
administration to 36 months were 15.82±18.25 (12 months 
before to baseline), 8.10±10.01 (baseline to 12 months), 
6.45±11.46 (12 months to 24 months), and 3.80±6.25 
(24 months to 36 months) (Figure 4). Though ACAI values 
Table 2 The changes of dosage of cinacalcet hydrochloride, intravenous calcitriol analogs, and phosphate binders during the study
Baseline Month 12 Month 24 Month 36
Cinacalcet hydrochloride (mg/day) 25±0 48.9±27.4 47.8±27.9 46.2±29.8
Intravenous calcitriol analogs
Calcitriol dose equivalents (μg/week) 1.56±1.26 1.41±1.22 1.51±1.18 1.53±1.18
 Subjects (%) 70 74 74 74
Calcium carbonate (g/day)* 2.00±0.87 2.00±0.95 1.92±0.89 2.03±0.92
 Subjects (%) 78.3 78.3 82.6 78.3
Sevelamer hydrochloride (g/day)* 3.75±2.25 3.45±2.09 3.00±1.98 2.63±1.79
 Subjects (%) 13 21.7 13 17.4
Lanthanum carbonate (g/day)* 0 0 1.18±0.64 1.15±0.67
 Subjects (%) 0 0 65.2 65.2
Notes: *Average daily doses in patients treated with each phosphate binder. Values are means ± standard deviation. 1.5 µg calcitriol =10 µg maxacalcitol.
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Figure 3 The change in aortic calcification area index (ACAI) from -12 months to 36 months for an individual subject (A) and the mean ACAI value over the observation 
period (B). The mean ACAI value was 21.4% at baseline, 23.9% at 12 months, 23.7% at 24 months, and 24.3% at 36 months.
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Figure 4 The annual percentage changes of aortic calcification area index (ACAI) from -12 months to 36 months. The values are 15.82±18.25 (-12 months to baseline), 
8.10±10.01 (baseline to 12 months), 6.45±11.46 (12 months to 24 months) and 3.80±6.25 (24 months to 36 months). The increase in ACAI/year from 12 months to 
24 months was significantly suppressed, compared to that of -12 months to baseline (P=0.017). Moreover, the increase in ACAI/year from 24 months to 36 months was 
significantly suppressed (P=0.001) *P,0.05; **P,0.01.  
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were not decreased in any of the subjects by cinacalcet 
administration, the percentage increase of ACAI/year was 
gradually suppressed. Especially, the increase in ACAI/year 
between 24 and 36 months was significantly suppressed 
compared to that of between 12 months before cinacalcet 
administration and baseline (P=0.001).
Factors associated with progression  
of aortic calcification
To determine potential factors responsible for the suppression 
of increase in ACAI/year, we examined associations between 
percentage changes in ACAI/year and biochemical response 
to cinacalcet by univariate and multivariate linear regression 
models (Tables 3 and 4). Eventually, female sex and reduc-
tion in ∆P or ∆Ca × P were independent determinants of 
suppression of increase in ACAI scores. Additionally, there 
was no significant difference in the suppression of ACAI/year 
between the group treated with lanthanum carbonate (n=15) 
and the other group (n=8) (data not shown).
Discussion
Vascular and cardiac valve calcification are important 
 predictors of cardiovascular disease and mortality among 
dialysis patients,28,29 and abdominal aortic calcification is 
also associated with coronary artery calcification, cardio-
vascular events, and mortality.2,3,30,31 Wilson et al reported 
Table 3 Univariate regression analysis of factors associated with 
the percent change of acaI between 24 months and 36 months, 
and between 12 months before cinacalcet administration and 
baseline
%ACAI (month 24/36/
month −12/0)**
R P-value
age 0.059 0.788
sex 0.533 0.009*
Diabetes mellitus 0.094 0.671
hemodialysis duration 0.340 0.112
ca 0.263 0.226
∆ca 0.029 0.895
P 0.340 0.113
∆P 0.632 0.001*
ca × P 0.344 0.108
∆ca × P 0.622 0.002*
iPTh 0.008 0.972
∆iPTh 0.138 0.531
alP 0.096 0.664
∆alP 0.127 0.564
Notes: *P,0.05; **[ACAI (month 36)/ACAI (month 24)/ACAI (month 0)/ACAI 
(month -12)].
Abbreviations: ACAI, aortic calcification area index; ALP, alkaline phosphatase; 
ca, calcium; P, inorganic phosphate; iPTh, intact parathyroid hormone.
Table 4 stepwise multivariate regression analysis of factors 
associated with the percent change of acaI between 24 months 
and 36 months, and between 12 months before cinacalcet 
administration and baseline
Dependent 
variable
Independent  
variable
β t P-value
%ACAI  
(month 24/36/ 
month -12/0)*
∆P 0.539 3.533 0.002
Sex (male:0, 
female:1)
-0.41 -2.688 0.014
R2=0.559, F value 12.681, 
P,0.001
∆ca × P 0.524 3.36 0.003
Sex (male:0,  
female:1)
-0.407 -2.608 0.017
R2=0.542, F value 11.850, 
P,0.001
∆P 0.632 3.74 0.001
R2=0.400, F value 13.989, 
P=0.001
Note: *[ACAI (month 36)/ACAI (month 24)]/[ACAI (month 0)/ACAI (month -12)].
Abbreviations: ACAI, aortic calcification area index; Ca, calcium; P, inorganic 
phosphate.
that abdominal aortic calcium deposits, detected by lumbar 
radiograms, are a marker of atherosclerotic disease and an 
independent predictor of subsequent vascular morbidity and 
mortality.32 At present, the effects of cinacalcet on coronary 
artery calcification have been tested in several studies, 
whereas little has been investigated regarding the effects 
of cinacalcet on abdominal aortic calcification. Therefore, 
we focused on changes of abdominal aortic calcification 
in patients on dialysis to assess the effects of cinacalcet on 
vascular calcification.
In our study protocol, we employed MDCT scans and 
evaluated changes of abdominal aortic calcification more 
precisely by calculating ACAI, while calcification was 
measured by plain lateral radiographs in the previous CORD 
(Calcification Outcome in Renal Disease) study.33 Moreover, 
to our knowledge, this is the first attempt to assess changes of 
vascular calcification in hemodialysis patients using MDCT 
for a period of 4 years. In addition, the studied population in 
the current study was relatively young and included fewer 
diabetes patients with longer dialysis duration compared with 
those in European and US registries.
To evaluate vascular calcification in hemodialysis patients, 
we have to take the effect of calcitriol analogs into account, 
since it has been suggested that calcitriol analog administration 
progresses calcification in a dose-dependent manner. In the 
ADVANCE study,24 patients on hemodialysis with SHPT were 
divided into a calcitriol analog group and a calcitriol analog plus 
cinacalcet group randomly, and they were observed for 52 weeks. 
The result suggested that cinacalcet  attenuates the progression 
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of coronary artery calcification score, cardiac valve calcifica-
tion, and calcification of the thoracic aorta. However, doses of 
calcitriol analogs were significantly decreased in the calcitriol 
analog plus cinacalcet group during the study, indicating that 
administration of calcitriol analogs might affect the progression 
of vascular calcification. On the other hand, in the EVOLVE 
(EValuation Of Cinacalcet HCl Therapy to Lower CardioVas-
cular Events) study, there were no significant differences in the 
incidence of cardiovascular events between the cinacalcet group 
and placebo group after 64 months of cinacalcet administra-
tion. Actually, baseline characteristics between the two groups, 
including cardiovascular morbidity, were imbalanced, and many 
patients in the cinacalcet group had their treatment aborted.34 
Even after completion of these trials, further investigation is 
needed to clarify the clinical benefits of cinacalcet.
In the current study, the influence of calcitriol analogs 
on vascular calcification can be excluded, in contrast to the 
ADVANCE study, since doses of calcitriol analogs were 
stable during the study period. Thus, it is suggested that 
slower progression of aortic calcification in our subjects can 
be attributed to the administration of cinacalcet. The actual 
ACAI value did not decrease after cinacalcet administration, 
but the annual change of the ACAI from 24 to 36 months 
was found to be significantly suppressed compared to from 
12 months before to baseline. Though almost all of the 
patients were outside the target levels of serum calcium and 
phosphorus at baseline, apparent improvement in those levels 
was observed after 36 months of cinacalcet administration. 
Moreover, univariate and multivariate linear regression 
analyses revealed that lower levels of serum phosphorus were 
associated with the suppression of vascular calcification. 
Based on these results, the progression of vascular calcifica-
tion may be suppressed by correcting the levels of phosphorus 
properly via the effect of cinacalcet, and it is suggested that 
starting cinacalcet at an earlier stage of hemodialysis could 
prevent progression of vascular calcification.
Though several reports have suggested the effect of 
cinacalcet against vascular calcification, there remains a 
fundamental question as to how calcimimetics work on 
the vascular wall in dialysis patients. The calcium-sensing 
receptor is a target for therapeutic manipulation, since it 
proved to be expressed in aortic smooth-muscle cells. In a 
recent animal experiment, cinacalcet was considered to be 
a potential arterial relaxant candidate, acting predominantly 
by inhibiting Ca2+ influx through L-type Ca2+ channels into 
vascular smooth muscle.35 However, whether cinacalcet has 
a direct effect on smooth-muscle cell calcification remains 
uncertain, and this question needs to be elucidated in future 
investigations. Recently, cinacalcet has been reported to 
suppress serum fibroblast growth factor-23 levels and reduce 
serum phosphate concentration.36
There are several limitations in the current clinical investi-
gation. The sample size of the enrolled patients was small, the 
study was not randomized or double-blinded, and there was 
no control group. The target range of intact PTH at 60–180 
pg/mL was recommended in the JSDT guideline at the initia-
tion of the study, but it was revised in 2012, and the target 
levels of intact PTH in the patients undergoing hemodialysis 
is recommended to be 60–240 pg/mL.37 Since the target was 
rather lower compared with Kidney Disease Outcomes Qual-
ity Initiative guidelines (150–300 pg/mL) and Kidney Disease 
Improving Global Outcomes guidelines (two to nine times the 
upper normal limit for the assay), it can be associated with a 
high risk for adynamic bone disease. In the evaluation of aorta 
calcification, the ACAI was measured by using MDCT. The 
area above bifurcation of the common iliac artery was scanned 
ten times at 1 cm intervals, but the current method has not been 
validated by clinical studies with larger populations. In addi-
tion, the ACAI reflects both intimal and medial calcification, 
and fails to measure intimal calcification specifically, which is 
more tightly associated with atherosclerosis. Finally, we could 
not completely rule out the beneficial effects of lanthanum 
carbonate and other phosphate binders on the progression of 
aorta calcification. Lanthanum carbonate became commer-
cially available in our country 12 months after our investigation 
started, and actually 65.2% of the subjects had been adminis-
trated lanthanum carbonate at the end of the study.
Conclusion
We clearly demonstrated that use of cinacalcet obviously 
suppressed the progression of abdominal aortic calcification 
throughout the observation period using MDCT imaging. 
Longer-term, ie, 3-year, administration of cinacalcet may 
reduce arterial calcification and achieve appropriate calcium 
and phosphorus levels, bringing about a reduction in the inci-
dence of cardiovascular events and mortality in patients on 
hemodialysis. The percentage of calcification increased with 
time, even with cinacalcet treatment, and the therapy may be 
palliative rather than curative. To conclude that cinacalcet is 
truly clinically beneficial in preventing vascular calcification, 
larger randomized clinical trials with properly optimized pro-
tocols, such as early initiation of the agent, are required.
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